170 related articles for article (PubMed ID: 32654405)
1. High-resolution crystal structures of the botulinum neurotoxin binding domains from subtypes A5 and A6.
Davies JR; Britton A; Liu SM; Acharya KR
FEBS Open Bio; 2020 Aug; 10(8):1474-1481. PubMed ID: 32654405
[TBL] [Abstract][Full Text] [Related]
2. High resolution crystal structures of Clostridium botulinum neurotoxin A3 and A4 binding domains.
Davies JR; Rees J; Liu SM; Acharya KR
J Struct Biol; 2018 May; 202(2):113-117. PubMed ID: 29288126
[TBL] [Abstract][Full Text] [Related]
3. Crystal Structures of Botulinum Neurotoxin Subtypes A4 and A5 Cell Binding Domains in Complex with Receptor Ganglioside.
Gregory KS; Mojanaga OO; Liu SM; Acharya KR
Toxins (Basel); 2022 Feb; 14(2):. PubMed ID: 35202156
[TBL] [Abstract][Full Text] [Related]
4. Crystal Structures of the
Gregory KS; Newell AR; Mojanaga OO; Liu SM; Acharya KR
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077016
[No Abstract] [Full Text] [Related]
5. The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes.
Pellett S; Bradshaw M; Tepp WH; Pier CL; Whitemarsh RCM; Chen C; Barbieri JT; Johnson EA
mBio; 2018 Mar; 9(2):. PubMed ID: 29588398
[TBL] [Abstract][Full Text] [Related]
6. Isolation and Characterization of the Novel Botulinum Neurotoxin A Subtype 6.
Moritz MS; Tepp WH; Bradshaw M; Johnson EA; Pellett S
mSphere; 2018 Oct; 3(5):. PubMed ID: 30355669
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the catalytic domain of botulinum neurotoxin subtype A3.
Leka O; Wu Y; Li X; Kammerer RA
J Biol Chem; 2021; 296():100684. PubMed ID: 33891946
[TBL] [Abstract][Full Text] [Related]
8. A Comprehensive Structural Analysis of
Gregory KS; Acharya KR
Toxins (Basel); 2023 Jan; 15(2):. PubMed ID: 36828407
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of botulinum neurotoxin subtype A3 cell binding domain in complex with GD1a co-receptor ganglioside.
Gregory KS; Liu SM; Acharya KR
FEBS Open Bio; 2020 Mar; 10(3):298-305. PubMed ID: 31945264
[TBL] [Abstract][Full Text] [Related]
10. Structural characterisation of the catalytic domain of botulinum neurotoxin X - high activity and unique substrate specificity.
Masuyer G; Zhang S; Barkho S; Shen Y; Henriksson L; Košenina S; Dong M; Stenmark P
Sci Rep; 2018 Mar; 8(1):4518. PubMed ID: 29540745
[TBL] [Abstract][Full Text] [Related]
11. High Yield Preparation of Functionally Active Catalytic-Translocation Domain Module of Botulinum Neurotoxin Type A That Exhibits Uniquely Different Enzyme Kinetics.
Dhaliwal HK; Thiruvanakarasu N; Kumar R; Patel K; Ambrin G; Cai S; Singh BR
Protein J; 2017 Dec; 36(6):489-501. PubMed ID: 29030733
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the catalytic properties of the botulinum neurotoxin subtypes A1 and A5.
Wang D; Krilich J; Pellett S; Baudys J; Tepp WH; Barr JR; Johnson EA; Kalb SR
Biochim Biophys Acta; 2013 Dec; 1834(12):2722-8. PubMed ID: 24096023
[TBL] [Abstract][Full Text] [Related]
13. Purification, modeling, and analysis of botulinum neurotoxin subtype A5 (BoNT/A5) from Clostridium botulinum strain A661222.
Jacobson MJ; Lin G; Tepp W; Dupuy J; Stenmark P; Stevens RC; Johnson EA
Appl Environ Microbiol; 2011 Jun; 77(12):4217-22. PubMed ID: 21515732
[TBL] [Abstract][Full Text] [Related]
14. Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype.
Kull S; Schulz KM; Weisemann J; Kirchner S; Schreiber T; Bollenbach A; Dabrowski PW; Nitsche A; Kalb SR; Dorner MB; Barr JR; Rummel A; Dorner BG
PLoS One; 2015; 10(2):e0116381. PubMed ID: 25658638
[TBL] [Abstract][Full Text] [Related]
15. Structural Features of
Gregory KS; Mahadeva TB; Liu SM; Acharya KR
Toxins (Basel); 2022 May; 14(5):. PubMed ID: 35622602
[TBL] [Abstract][Full Text] [Related]
16. Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation.
Kumaran D; Eswaramoorthy S; Furey W; Navaza J; Sax M; Swaminathan S
J Mol Biol; 2009 Feb; 386(1):233-45. PubMed ID: 19118561
[TBL] [Abstract][Full Text] [Related]
17. A viral-fusion-peptide-like molecular switch drives membrane insertion of botulinum neurotoxin A1.
Lam KH; Guo Z; Krez N; Matsui T; Perry K; Weisemann J; Rummel A; Bowen ME; Jin R
Nat Commun; 2018 Dec; 9(1):5367. PubMed ID: 30560862
[TBL] [Abstract][Full Text] [Related]
18. 8-Hydroxyquinoline and hydroxamic acid inhibitors of botulinum neurotoxin BoNT/A.
Dickerson TJ; Smith GR; Pelletier JC; Reitz AB
Curr Top Med Chem; 2014; 14(18):2094-102. PubMed ID: 25335884
[TBL] [Abstract][Full Text] [Related]
19. Structural and biochemical characterization of the protease domain of the mosaic botulinum neurotoxin type HA.
Lam KH; Sikorra S; Weisemann J; Maatsch H; Perry K; Rummel A; Binz T; Jin R
Pathog Dis; 2018 Jun; 76(4):. PubMed ID: 29688327
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy.
Yin L; Masuyer G; Zhang S; Zhang J; Miyashita SI; Burgin D; Lovelock L; Coker SF; Fu TM; Stenmark P; Dong M
PLoS Biol; 2020 Mar; 18(3):e3000618. PubMed ID: 32182233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
